Announcements
- LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- LAVA Announces Annual Meeting of Shareholders
- LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
- LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
- LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
- LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
- LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
- Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
More ▼
Key statistics
On Thursday, LAVA Therapeutics NV (4PKB:FRA) closed at 1.89, 80.00% above the 52 week low of 1.05 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.73 |
---|---|
High | 1.92 |
Low | 1.73 |
Bid | 1.88 |
Offer | 2.00 |
Previous close | 1.80 |
Average volume | 408.89 |
---|---|
Shares outstanding | 26.29m |
Free float | 18.74m |
P/E (TTM) | -- |
Market cap | 52.05m USD |
EPS (TTM) | -1.07 USD |
Data delayed at least 15 minutes, as of Jul 25 2024 20:55 BST.
More ▼